Zai Lab Secures Hong Kong Approval for TIVDAK in Advanced Cervical Cancer

Zai Lab announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with r...

September 02, 2025 | Tuesday | News
Ascletis’ ASC30 Oral Tablet Shows 2.3–3.3x Greater Drug Exposure Than Orforglipron in U.S. Phase Ib Study

ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. -...

August 28, 2025 | Thursday | News
Fosun Pharma Grants Global Rights (Ex-China) for Innovative Respiratory Drug XH-S004 to Expedition Therapeutics

Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...

August 12, 2025 | Tuesday | News
Akeso Doses First Patient in Phase III Trial of Ivonescimab for Limited-Stage Small Cell Lung Cancer

Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...

August 11, 2025 | Monday | News
HKBU-Led Team Unveils Magnetically Guided Nanorobot to Combat Pollution, Bacteria, and Biofilms

A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped with silver and gold nanorods...

August 04, 2025 | Monday | News
Akeso Doses First Patient in Pivotal Phase III Trial of Ivonescimab for IO-Resistant NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...

July 31, 2025 | Thursday | News
Harbour BioMed and Otsuka Enter $670M+ Global Agreement Across Asia, US, and Europe to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...

June 23, 2025 | Monday | News
Ascletis Reports Positive Phase Ib Results for Oral GLP-1R Agonist ASC30 in Obesity, Supporting Phase IIa Advancement

 Ascletis Pharma Inc.  announces  positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...

April 23, 2025 | Wednesday | News
Akeso Secures NMPA Approval for Ebdarokimab to Treat Moderate-to-Severe Plaque Psoriasis in Adults

Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...

April 21, 2025 | Monday | News
Akeso Advances Global Leadership in Bispecific Antibodies with Approvals for Ivonescimab and Cadonilimab

Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...

March 31, 2025 | Monday | News
Rhythm Pharmaceuticals Reacquires Rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau

 Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...

March 24, 2025 | Monday | News
Life Molecular Imaging & St. Teresa’s Hospital Launch Neuraceq® in Hong Kong for Early Alzheimer’s Diagnosis

Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be av...

March 18, 2025 | Tuesday | News
Akeso’s Ivonescimab Phase III Study Results Published in The Lancet, Paving the Way for New NSCLC Treatment

Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...

March 07, 2025 | Friday | News
HBM Alpha Therapeutics Partners with Global Business Partner to Advance CRH-targeting Therapy for Endocrine Disorders

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...

February 26, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close